Abstract 17401: Ranolazine: A Novel Anti-ischemic Drug in Preventing Post-operative Af in Patients Undergoing Coronary Artery Bypasses Grafting: Meta-analysis
Introduction: Atrial fibrillation (AF) is common after coronary artery bypass grafting (CABG). Ranolazine is a novel drug used in the treatment of angina, which also has antiarrhythmic properties. Recent studies demonstrated the benefit of ranolazine in preventing post-operative AF (POAF) in patients undergoing CABG.
Hypothesis: To assess the role of ranolazine in preventing POAF in patients undergoing CABG surgery.
Methods: We performed comprehensive search of PubMed, MEDLINE, and Cochrane library database on the study assessing the effectiveness of ranolazine in preventing POAF by comparing it with standard therapy. Meta-analysis was performed by fixed effect model by entering POAF events and the total population from each study. Data are expressed as Odds ratio (OR) with 95% confidence interval (CI).
Results: A total of three studies with 628 patients (259 pts in ranolazine group, 369 pts in standard therapy group) were included in the meta-analysis. In pooled analysis, ranolazine was associated with 54% reduction in post-operative AF events compared to standard therapy [odds ratio = 0.46 (0.31, 0.70), P<0.001]. The number needed to be treated was 7.14. In one of the study, more patients in ranolazine group (52.2%) had symptomatic hypotension three days after the surgery.
Conclusions: Ranolazine may prove beneficial in the prevention of POAF following CABG. However, because of small number of studies further research with large randomized clinical trial is warranted to determine specific dose and duration of ranolazine therapy.
Author Disclosures: C. Trivedi: None. L. Di Biase: Speakers Bureau; Modest; Biotronik, EpiEP, AtriCure, Inc.. Consultant/Advisory Board; Modest; Hansen Medical, St. Jude Medical. S. Mohanty: None. C. Gianni: None. M. Gunes: None. Y. Gökoglan: None. A. Natale: Speakers Bureau; Modest; Boston Scientific Corp, Biotronik, Medtronic, Inc.. Consultant/Advisory Board; Modest; Janssen Pharmaceuticals, St. Jude Medical, Biosense Webster Inc..
- © 2015 by American Heart Association, Inc.